Marrone Bio Innovations EBIT

As of the most recent data (March 2022), MBII shows a EBIT of $-19M. That compares with $-11M in the prior-year period — down 75.3% year over year. That is below the Materials sector average of $13B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MBII's EBIT is now $-19M (was $-11M) — a 75.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Marrone Bio Innovations is outperforming or lagging.

The Materials sector average EBIT is about $13B. Marrone Bio Innovations is at $-19M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how MBII stacks up against individual peers as well.

Tracking MBII's ebit over time shows whether Marrone Bio Innovations is scaling, shrinking, or reshaping that part of the business. The current reading is $-19M That compares with $-11M in the prior-year period — down 75.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Marrone Bio Innovations's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-19M) with ownership activity and broader fundamentals.